Akeso's Ivonescimab Secures Breakthrough Therapy Designation
Akeso announced that its bispecific antibody, ivonescimab, has secured a Breakthrough Therapy Designation in China for first-line treatment of triple-negative breast cancer.
Ivonescimab is a first-in-class PD-1/VEGF bispecific antibody, used in combination with chemotherapy.
Always consult a qualified healthcare professional for medical advice, diagnosis, or treatment.
Akeso's designation is aligned with the United Nations Sustainable Development Goals (SDGs) - SDG 3, SDG 4, SDG 5, SDG 6, SDG 10 & SDG 12.
- Company: Akeso (9926.HK)
- Designation: Breakthrough Therapy Designation
- Location: China
Author summary: Akeso's ivonescimab gets breakthrough therapy designation.
More News
- Could Melatonin Be Silently Harming Your Heart?
- Exclusive: Meati in trouble again as firm misses payroll. ‘People are in group chats begging for answers’
- Live updates: Poll results begin to arrive in 2025 Yukon elections
- Social caravan heads to COP30 to denounce agribusiness megaprojects
- Guest article: COP30 is our chance to achieve resilient global food security—by empowering smallholders
- How the UAE's regional wars of chaos and plunder will eventually come home
- Live updates: Poll results begin to arrive in 2025 Yukon elections